OakChart

Entera Bio Ltd

ENTXHealthcare·Biotechnology·Israel·Small·NASD·Nov 11 • 3:59 PM ET

3.22-0.02 (-0.62%)
2026-11-12 02:22 CET
Market cap
564.21 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-29.43 USD m
Free cash flow, TTM
-16.08 USD m
EPS diluted, TTM
-0.39
P/E
-
Compare

Price

ENTX against its 20, 50 and 200-day averages
2050200earnings
1.002.003.004.0041.7M83.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ENTXclose 3.2220-day 3.0450-day 2.89200-day 1.973.2252w high

23.3% under the 52-week high of 4.20 on 27 Jul 2026. 52-week low 0.91 on 30 Mar 2026. Last 15 sessions, 24.6% high to low

Volume 0.23× normal · the line is the 50-bar volume average

Profile

ENTX
52-week range, 70% of the way up
0.914.20

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. It s pipeline include PTH(1-34), GLP-1 and GLP-2. The company was founded on September 30, 2009 and is headquartered in Jerusalem, Israel.

Employees22
IPOJun 28, 2018
Beta1.45
ATR, 14d0.21
Rel volume0.23
Short float5.09%
Insider own20.20%
Inst own18.16%

Snapshot

6 groups

Valuation

Index-
Market Cap560.73M
Enterprise Value288.71M
Income-29.43M
Sales0.00M
Book/sh1.58
Cash/sh1.56
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees22
IPOJun 28, 2018

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B2.04
P/C2.06
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio128.41
Current Ratio128.41
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.39
EPS next Y-0.41
EPS next Q-0.17
EPS this Y-99.00%
EPS next Y18.59%
EPS next 5Y-16.72%
EPS past 3/5Y18.28% 16.47%
Sales past 3/5Y-32.07% -35.11%
EPS Y/Y TTM-59.89%
Sales Y/Y TTM-100.00%
EPS Q/Q-58.09%
Sales Q/Q-
EarningsNov 06 AMC
EPS/Sales Surpr.-69.23% -

Ownership

Insider Own20.20%
Insider Trans0.00%
Inst Own18.16%
Inst Trans8.61%
ROA-19.99%
ROE-20.33%
ROIC-10.72%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA205.87%
SMA5011.34%
SMA20063.52%
Trades-

Technical

Shs Outstand173.92M
Shs Float138.97M
Short Float5.09%
Short Ratio15.50
Short Interest7.07M
52W High4.20 -23.33%
52W Low0.91 253.84%
Volatility7.09% 7.76%
ATR (14)0.21
RSI (14)60.11
Beta1.45
Rel Volume0.23
Avg Volume456.06K
Volume103,432

Performance

Perf Week3.54%
Perf Month29.32%
Perf Quarter12.20%
Perf Half Y149.61%
Perf YTD65.98%
Perf Year6.98%
Perf 3Y360.00%
Perf 5Y-15.49%
Perf 10Y-
Recom1.00
Target Price10.00
Prev Close3.24
Price3.22
Change %-0.62%

Analyst ratings

latest 4 of 4
DateActionAnalystRating changeTargetImplied
Sep 25, 2026InitiatedGGuggenheimBuy$11+241.6%
Sep 22, 2026InitiatedCCantor FitzgeraldOverweight
Sep 18, 2026InitiatedLLeerink PartnersOutperform$9+179.5%
Mar 22, 2021InitiatedAAegis CapitalBuy$12+272.7%

Peers

Mkt cap
TickerCompanyMkt cap
RANIRani Therapeutics Holdings Inc79.18M
MBXMBX Biosciences Inc2.87B
ASNDAscendis Pharma A/S17.03B
VKTXViking Therapeutics Inc3.63B
OPKOpko Health Inc1.27B
SPRYARS Pharmaceuticals Inc397.09M
AQSTAquestive Therapeutics Inc449.96M
LPCNLipocine Inc17.61M
NVONovo Nordisk ADR137.48B
AMGNAMGEN Inc253.21B

Insider trading

6 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Germano Geno JDirectorMar 09 '26Buy1.3020,00026,00040,000Mar 11 08:30 AM
Ellis SeanDirectorMar 05 '26Buy1.2310,00012,300188,098Mar 09 08:30 AM
Rubin Steven DDirectorFeb 12 '26Buy1.495,0007,45015,000Feb 17 08:30 AM
Rubin Steven DDirectorFeb 09 '26Buy1.2010,00012,00010,000Feb 11 08:44 AM
Ellis SeanDirectorFeb 09 '26Buy1.2418,00022,320178,098Feb 11 08:42 AM
Toledano Miranda JayneChief Executive OfficerDec 29 '25Buy1.8111,00019,912426,575Dec 30 06:01 AM

Held by

AUM
TickerCompanyAUM
PEPTREX Peptide ETFAUM: 3.32M

News

latest 14 of 200
  • Gilead's Latest Deal Shows Big Pharma's Appetite for Oral Peptides. Which Stocks Are Worth Watching? (FinanceWire)
  • Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX) (FinanceWire)
  • Entera Bio Receives New Overweight Rating From Cantor Fitzgerald (NASDAQ: ENTX) (FinanceWire) -5.70%
  • Entera Receives $9 Price Target and New 'Outperform' Rating From Leerink Partners (NASDAQ: ENTX) (FinanceWire)
  • Entera is on the Cusp of the Trial That Could Unlock America's Osteoporosis Drug Market (NASDAQ: ENTX) (FinanceWire)
  • Entera Bio shares slip as Q2 loss comes in wider than expected (InvestorsHub) +5.92%
  • Why the World's Leading Healthcare Funds All Wanted a Piece of Entera Bio (NASDAQ: ENTX) (FinanceWire)
  • Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE (PR Newswire) -7.98%
  • After Crinetics' $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story? (FinanceWire) +9.88%
  • America's Osteoporosis Crisis and the Oral Peptide Player You Should Watch (NASDAQ: ENTX) (FinanceWire)
  • ENTX Stock On Track For Best Day In Over 5 Years Whats Driving The Rally? (Stocktwits) +22.31%
  • Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners (PR Newswire) -5.56%
  • Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates (GlobeNewswire) +9.71% -11.50%
  • Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-06-0.110-0.065-0.000.004
2026Q22026-08-07-0.140-0.080-0.1450.000.001
2026Q12026-05-08-0.070-0.080-0.0730.000.001
2025Q42026-03-27-0.060-0.090-0.0650.00-1
2025Q32025-11-14-0.070-0.090-0.068-0.04-1
2025Q22025-08-08-0.060--0.057-0.04--
2025Q12025-05-090.060-0.070-0.0590.04-1
2024Q42025-03-28-0.060-0.080-0.0610.040.041
2024Q32024-11-08-0.080-0.050-0.0800.040.041
2024Q22024-08-09-0.060-0.060-0.0580.060.001
2024Q12024-05-100.050-0.060-0.0550.000.001
2023Q42024-03-08-0.060-0.080-0.0670.000.001
2023Q32023-11-14-0.080-0.090-0.0830.000.001
2023Q22023-08-11-0.080-0.070-0.0810.010.001
2022S22023-03-31-0.100-0.115-0.010.05-
2022Q32022-11-10---0.107---

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY0.890-0.810-0.8890.24-0.13
2020FY0.550-0.560-0.6090.370.14
2021FY-0.470-1.053-0.4660.570.54
2022FY-0.450-0.490-0.4540.130.18
2023FY-0.310-0.320-0.3060.000.00
2024FY-0.250-0.280-0.2530.180.14
2025FY-0.250-0.280-1.2900.040.04
2026FY--0.498--0.00
2027FY--0.405--0.00
2028FY--0.398--0.00
2029FY--0.353--7.63
2030FY--0.450--57.47

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-093000.000.000.00
2026Q4S2026-11-073000.000.000.00
2026Q4S2026-10-013000.000.000.00
2026Q4S2026-09-234000.000.000.00
2026Q4S2026-09-213000.000.000.00
2026Q4S2026-09-172000.000.000.00
2026Q4S2026-08-101000.000.000.00
2026Q4S2026-05-111000.000.000.00
2026Q4S2026-04-241000.000.000.00
2026Q4E2026-11-09412-0.17-0.26-0.04
2026Q4E2026-11-07400-0.15-0.21-0.05
2026Q4E2026-10-01400-0.15-0.21-0.05
2026Q4E2026-09-23500-0.14-0.21-0.05
2026Q4E2026-09-22400-0.13-0.21-0.05

Estimate history

EPS, annual-0.962-1.295-0.889-0.609-0.466-0.454-0.306-0.253-0.248-0.3911
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.08-0.061-0.059-0.057-0.068-0.065-0.073-0.145-0.108
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00.50.2360.3650.5710.13400.1810.0420
Period201720182019202020212022202320242025TTM
Sales, quarterly0.0420.0820.042000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual11.63811.4617.86521.05828.80428.8135.47638.83746.179173.922
Period201720182019202020212022202320242025MRQ
Shares, quarterly36.51238.83745.42145.45245.66546.17946.62249.29173.922
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.040.180.000.130.570.360.240.50
Cost of Goods Sold Incl. D&A0.030.070.170.060.170.370.300.450.05
Gross Profit-0.03-0.030.01-0.06-0.030.200.07-0.210.45
Selling, General and Administrative Excl. Other18.3811.509.598.8813.0412.4611.2311.2411.31
Research and Development12.065.974.504.455.786.776.386.968.52
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-18.41-11.53-9.59-8.94-13.07-12.26-11.17-11.45-10.86
Interest Expense0.000.00---0.030.030.08-
Unusual Expense0.000.000.000.000.000.000.00-0.74-0.52
Net Income Before Taxes-29.43-11.44-9.53-8.86-12.93-12.25-11.20-10.80-10.30
Income Taxes0.000.000.010.030.14-0.060.020.000.00
Consolidated Net Income-29.43-11.44-9.54-8.89-13.07-12.19-11.22-10.80-10.30
Net Income From Continuing Operations-29.43-11.44-9.54-8.89-13.07-12.19-11.22-10.80-10.30
Net Income-29.43-11.44-9.54-8.89-13.07-12.19-11.22-10.80-10.30
EPS (Recurring)-0.20-0.25-0.25-0.31-0.45-0.47-0.61-0.93-1.34
EPS (Basic, Before Extraordinaries)-0.39-0.25-0.25-0.31-0.45-0.47-0.61-0.89-1.30
EPS (Diluted)-0.39-0.25-0.25-0.31-0.45-0.47-0.61-0.89-1.30
EBITDA-18.38-11.50-9.54-8.88-13.00-12.21-11.11-11.22-10.81
Non-Operating Income (Expense)-11.020.090.060.080.130.050.000.000.03
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.832.752.021.331.731.430.691.481.23
Price To Sales Ratio-2,133.59440.99-156.94128.8454.49110.1448.53
Gross Margin--71.434.97--23.1334.6817.81-89.8389.20
Operating Margin--27,450.00-5,295.58--9,752.24-2,147.64-3,059.73-4,853.39-2,172.20
Net Margin--27,235.71-5,271.27--9,754.48-2,134.33-3,072.88-4,574.15-2,060.80
Shares Outstanding173.9246.1838.8435.4828.8128.8021.0617.8611.46
Market Capitalization564.21564.2178.0817.2921.0381.0319.6926.0134.86

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.040.08
Cost of Goods Sold Incl. D&A0.010.010.010.010.010.010.040.08
Gross Profit-0.01-0.01-0.01-0.01-0.01-0.010.000.00
Selling, General and Administrative Excl. Other7.264.553.533.043.252.662.562.34
Research and Development4.923.192.241.711.641.511.121.20
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-7.26-4.56-3.54-3.04-3.26-2.67-2.56-2.34
Interest Expense0.000.000.000.000.000.000.000.01
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-15.60-7.31-3.51-3.02-3.20-2.66-2.57-2.34
Income Taxes0.000.000.000.000.000.000.000.01
Consolidated Net Income-15.60-7.31-3.51-3.02-3.20-2.66-2.57-2.36
Net Income From Continuing Operations-15.60-7.31-3.51-3.02-3.20-2.66-2.57-2.36
Net Income-15.60-7.31-3.51-3.02-3.20-2.66-2.57-2.36
EPS (Recurring)-0.11-0.14-0.07-0.07-0.07-0.06-0.06-0.06
EPS (Basic, Before Extraordinaries)-0.11-0.14-0.07-0.07-0.07-0.06-0.06-0.06
EPS (Diluted)-0.11-0.14-0.07-0.07-0.07-0.06-0.06-0.06
EBITDA-7.26-4.55-3.53-3.04-3.25-2.66-2.56-2.33
Non-Operating Income (Expense)-8.33-2.750.030.030.060.01-0.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.820.620.670.710.930.510.600.45
Price To Sales Ratio---2,133.01729.13536.08330.68454.89
Gross Margin------0.000.00
Operating Margin-------6,102.38-2,850.00
Net Margin-------6,111.90-2,875.61
Shares Outstanding173.9249.2946.6246.1845.6645.4545.4238.84
Market Capitalization564.2187.2451.7588.9687.6786.3670.9578.08

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments14.888.6611.0212.3124.898.5915.2211.5411.75
Short Term Receivables0.220.130.000.250.180.260.280.720.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.200.190.240.290.250.260.140.200.67
Total Current Assets15.308.9711.2612.8525.339.1115.6412.4712.42
Net Property, Plant & Equipment0.600.330.490.230.400.570.460.220.21
Total Investments and Advances0.090.080.000.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.000.600.650.65
Deferred Tax Assets-0.000.010.040.220.00---
Other Assets0.010.010.010.010.050.050.000.000.00
Total Assets15.999.3911.7713.1325.999.7216.7013.3413.28
Short Term Debt Incl. Current Port. of LT Debt0.230.170.130.090.180.190.180.000.00
Accounts Payable0.450.130.080.020.170.160.330.470.60
Income Tax Payable---0.000.130.00---
Other Current Liabilities1.520.870.871.232.681.494.081.311.42
Total Current Liabilities2.201.181.091.343.161.844.591.792.02
Long Term Debt0.260.100.260.000.120.240.120.0037.35
Provision for Risks Charges0.040.030.030.030.140.130.070.070.07
Other Liabilities0.390.000.000.000.000.000.001.375.40
Total Liabilities2.891.311.381.373.422.214.783.2344.84
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity13.108.0810.3911.7522.577.5111.9210.12-31.56
Total Shareholders Equity13.108.0810.3911.7522.577.5111.9210.12-31.56
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity13.108.0810.3911.7522.577.5111.9210.12-31.56
Total Liabilities & Stockholders Equity15.999.3911.7713.1325.999.7216.7013.3413.28
Book Value Per Share0.280.210.290.410.780.360.670.88-2.71
Tangible Book Value Per Share0.280.210.290.410.780.360.630.83-2.77
Full-Time Employees2220373823182419-
Price to Book Ratio2.0512.002.771.473.593.413.21-1.06-1.14
Return on Assets-90.13-90.20-71.42-66.84-67.24-84.89-71.86-77.42-114.47
Return on Equity-108.01-103.34-80.30-76.17-83.39-115.46-97.98--
Return on Invested Capital-85.61-116.61-83.53-111.20-53.72-144.67-89.65-101.86-193.39
Quick Ratio6.947.6310.329.588.014.953.416.976.15
Current Ratio6.947.6310.329.588.014.953.416.976.15

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-29.83-11.44-9.54-8.89-13.07-12.19-11.22-10.80-10.30
Depreciation0.030.030.050.060.060.050.060.240.05
Other Funds (Non Cash)16.392.782.551.692.171.880.950.950.96
Funds from Operations-13.41-8.63-6.93-7.12-10.66-10.47-10.21-9.61-9.29
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-2.621.260.11-0.20-1.841.41-0.350.69-0.51
Cash from Operating Activities-16.03-7.37-6.82-7.31-12.50-9.06-10.56-8.92-9.80
Capital Expenditures-0.05-0.11-0.00-0.02-0.05-0.02-0.05-0.04-0.07
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments0.000.000.000.000.000.000.000.00-4.00
Purchase of Investments0.000.000.000.000.000.000.000.00-4.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.00-0.060.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.05-0.11-0.00-0.02-0.10-0.02-0.05-0.04-4.07
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock272.8713.714.486.040.0125.384.0512.779.62
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock272.8713.714.486.040.0125.384.0512.779.62
Proceedsfrom Stock Options-21.745.993.64-0.580.0021.813.9812.530.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.00-0.110.00
Change in Long Term Debt0.000.000.000.000.000.000.00-0.110.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.00-0.110.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities272.8713.714.486.040.0125.384.0512.659.62
Exchange Rate Effect--0.04-------
Net Change in Cash256.766.20-2.35-1.29-12.5916.30-6.563.69-4.24
Free Cash Flow-16.08-7.48-6.82-7.33-12.55-9.08-10.61-8.96-9.86
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.010.030.17-0.220.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments272.4218.4311.9314.8816.6018.87
Short Term Receivables0.090.020.000.220.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets3.960.450.570.200.410.44
Total Current Assets276.4618.9012.4915.3017.0119.31
Net Property, Plant & Equipment0.480.480.540.600.310.27
Total Investments and Advances0.090.100.090.090.090.08
Intangible Assets0.000.000.000.000.000.00
Other Assets0.010.010.010.010.010.01
Total Assets277.0419.4813.1315.9917.4119.67
Short Term Debt Incl. Current Port. of LT Debt0.210.200.180.230.170.19
Accounts Payable0.410.570.270.450.220.38
Other Current Liabilities1.541.331.121.521.191.27
Total Current Liabilities2.152.101.582.201.571.84
Long Term Debt0.190.230.260.260.040.01
Provision for Risks Charges0.040.040.040.040.030.03
Other Liabilities0.389.850.570.390.530.52
Total Liabilities2.7612.212.442.892.172.41
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity274.287.2710.6913.1015.2317.26
Total Shareholders Equity274.287.2710.6913.1015.2317.26
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity274.287.2710.6913.1015.2317.26
Total Liabilities & Stockholders Equity277.0419.4813.1315.9917.4119.67
Book Value Per Share1.580.150.230.280.330.38
Tangible Book Value Per Share1.580.150.230.280.330.38
Full-Time Employees272222222221
Price to Book Ratio2.057.723.915.825.064.45
Return on Assets-19.99-87.02-71.28-90.13-85.74-71.39
Return on Equity-20.33-138.92-82.33-108.01-99.43-82.22
Return on Invested Capital-5.68-97.60-32.01-22.57-20.95-15.38
Quick Ratio128.418.987.936.9410.8310.47
Current Ratio128.418.987.936.9410.8310.47

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-15.41-7.59-3.51-3.32-3.56-2.68
Depreciation0.010.010.010.010.010.01
Other Funds (Non Cash)11.273.610.680.830.990.54
Funds from Operations-4.13-3.97-2.82-2.49-2.56-2.14
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-3.150.33-0.270.46-0.180.49
Cash from Operating Activities-7.28-3.63-3.09-2.03-2.74-1.64
Capital Expenditures-0.02-0.000.00-0.03-0.05-0.03
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.02-0.000.00-0.03-0.05-0.03
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock262.1310.220.130.390.810.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock262.1310.220.130.390.810.00
Proceedsfrom Stock Options-14.14-0.180.00-7.430.62-0.02
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities262.1310.220.130.390.810.00
Net Change in Cash254.846.58-2.96-1.71-1.98-1.67
Free Cash Flow-7.30-3.64-3.09-2.06-2.79-1.67

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 181.00K 2025: 42.00K
Israel2024: 181.00K 2025: 42.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-305.09%7.1M138.8M501.68K
2026-10-154.00%5.5M138.8M1.86M
2026-09-301.83%2.4M131.7M1.79M
2026-09-150.97%1.3M131.7M2.63M
2026-08-310.67%0.9M131.7M2.54M
2026-08-140.73%1.0M130.7M2.53M
2026-07-3114.47%1.2M8.0M2.48M
2026-07-150.75%0.3M39.9M1.04M
2026-06-300.83%0.3M40.3M1.02M
2026-06-150.40%0.2M40.1M155.74K
2026-05-290.45%0.2M39.5M169.05K
2026-05-150.46%0.2M39.5M169.35K
2026-04-300.51%0.2M37.6M195.40K
2026-04-150.51%0.2M37.6M167.95K
2026-03-310.47%0.2M37.5M209.49K
2026-03-130.37%0.1M36.9M204.46K
2026-02-270.34%0.1M36.9M192.39K
2026-02-130.32%0.1M36.9M193.35K
2026-01-300.30%0.1M34.5M171.09K
2026-01-150.29%0.1M34.5M204.94K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.001.702.852.050.0000.000.000.966-0.0110.000
call2.000.003.702.010.00013.000.000.924-0.0100.001
call3.000.002.900.051.9681,6201.000.682-0.0490.002
call4.000.000.250.201.7342380.000.228-0.0140.001
call5.000.002.550.203.47711.000.000.294-0.0340.002
call6.000.002.550.004.1770.000.000.264-0.0390.002
call7.000.002.550.454.7233.000.000.246-0.0420.002
put1.000.002.550.005.3290.000.00-0.034-0.0110.000
put2.000.000.050.019.8111.000.00-0.139-0.0610.001
put3.000.000.900.605.37742.000.00-0.318-0.0490.002
put4.000.003.401.2017.5581.000.00-0.639-0.0250.002
put5.000.304.400.0018.5230.000.00-0.706-0.0330.002
put6.000.504.600.0012.6350.000.00-0.736-0.0380.002
put7.001.506.000.0015.9240.000.00-0.754-0.0410.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-068-KCurrent report2026-11-06SEC
2026-10-30SCHEDULE 13GSEC
2026-10-278-KCurrent report2026-10-27SEC
2026-10-14DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-14SEC
2026-10-068-KCurrent report2026-10-06SEC
2026-09-23PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-23SEC
2026-08-28EFFECTEffectiveness filing by commission orderSEC
2026-08-28424B3SEC
2026-08-21S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-08-213Initial statement of beneficial ownership of securities2026-08-18SEC
2026-08-188-KCurrent report2026-08-18SEC
2026-08-12DNotice of sales of securities on Form D (Regulation D)SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-07S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-078-KCurrent report2026-08-07SEC
2026-08-04SCHEDULE 13GSEC
2026-08-04SCHEDULE 13GSEC
2026-08-04SCHEDULE 13GSEC
2026-08-04SCHEDULE 13GSEC
2026-08-04SCHEDULE 13DSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-0338.30K200
2026-0241.77K300
2026-010000
2025-1219.91K100
2025-110000

Institutional holders

Manager% owned
Knoll Capital Management, LLC11.93%
BVF INC/IL4.92%
Siren, L.L.C.1.49%
RENAISSANCE TECHNOLOGIES LLC0.75%
Parkman Healthcare Partners LLC0.56%
Seven Fleet Capital Management LP0.39%
PNC FINANCIAL SERVICES GROUP, INC.0.16%
HRT FINANCIAL LP0.15%
Schonfeld Strategic Advisors LLC0.12%
GEODE CAPITAL MANAGEMENT, LLC0.10%

Funds

Fund% owned
VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND4.70%
VANGUARD DEVELOPED MARKETS INDEX FUND3.13%
iShares Core MSCI EAFE ETF2.64%
THE CONTINENTAL SMALL COMPANY SERIES2.19%
VANGUARD FTSE ALL-WORLD EX-US SMALL-CAP INDEX FUND1.22%
VANGUARD GLOBAL EX-U.S. REAL ESTATE INDEX FUND1.20%
iShares MSCI EAFE Small-Cap ETF1.19%
INTERNATIONAL CORE EQUITY 2 PORTFOLIO0.94%
VANGUARD EUROPEAN STOCK INDEX FUND0.76%
iShares Core MSCI Total International Stock ETF0.72%

OakChart. ENTX. Cached 15 minutes.